LupiARognoniASeccoGG. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients. Eur J Prev Cardiol2012. [Epub ahead of print 14 November 2012].
2.
OstojicMSagicDBeleslinB. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention2008; 3: 574–579.
3.
XuBDouKFHanYL. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J (Engl)2011; 124: 811–816.
4.
ByrneRAKufnerSTirochK. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart2009; 95: 1489–1494.
5.
MehilliJByrneRAWieczorekA. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J2008; 29: 1975–1982.
6.
Higgins JPT and Green S (eds). Cochrane handbook for systematic reviews of interventions Version 5.1.0. Updated March 2011. The Cochrane Collaboration, 2011. Chichester, West Sussex, England: John Wiley & Sons Ltd. Available from www.cochrane-handbook.org.
